CagriSema Side Effects: What the Trials Show

CagriSema’s side effects are mostly gastrointestinal, and while they’re common, the large majority are mild to moderate and fade over time. In the phase 3 trials, gastrointestinal issues affected roughly 80% of people on CagriSema, driven mainly by nausea, constipation, and vomiting, but relatively few people stopped treatment because of them. CagriSema is investigational and not FDA approved, so this comes from clinical trial data rather than real-world prescribing. Here’s the detailed side-effect picture and what it means.

Why the Side Effects Happen

CagriSema combines two drugs: cagrilintide (an amylin analog) and semaglutide (a GLP-1 drug). Both slow stomach emptying and act on appetite and fullness signals, which is exactly how they drive weight loss, but that same slowing of the gut is what produces most of the side effects. When your stomach empties more slowly and your digestive system adjusts to reduced appetite, nausea and related symptoms tend to follow, especially early on.

This is why the side effects are concentrated during the dose-escalation period. As the dose steps up over the first several months, your body is adapting, and that’s when symptoms peak. Once you reach a stable maintenance dose, most people find the symptoms settle considerably.

The Numbers From the Trials

The clearest data comes from the pivotal REDEFINE 1 trial, published in the New England Journal of Medicine in 2025, which studied CagriSema in adults with obesity. Gastrointestinal adverse events occurred in about 79.6% of the CagriSema group versus roughly 39.9% on placebo, and the specific symptoms broke down as follows.

The trial reported these events were mainly transient and mild-to-moderate in severity. Importantly, the discontinuation rate tells a reassuring story: only about 6% of CagriSema participants stopped due to adverse events, versus roughly 3.7% on placebo. In other words, despite the high frequency of GI symptoms, most people tolerated the drug well enough to stay on it.

How This Compares to Semaglutide Alone

CagriSema tends to produce more GI side effects than semaglutide (Wegovy) on its own, which makes sense given it’s a two-drug combination. The trade-off is more weight loss in exchange for somewhat higher rates of nausea and vomiting. For many people, the added weight loss is worth the tolerability cost, especially since the symptoms are usually manageable and improve over time. Consider a hypothetical patient who experiences noticeable nausea during the first couple of months of dose escalation, then finds it largely resolves once they reach their maintenance dose. That arc is typical.

Managing the Symptoms

While CagriSema isn’t available yet, the general strategies for GLP-1-class side effects are well established: eating smaller meals, avoiding high-fat and greasy foods, staying hydrated, and going slow on dose increases. Constipation often responds to fiber, fluids, and, if needed, over-the-counter remedies. These approaches apply broadly to this drug class.

It’s also worth noting that, as with other GLP-1-based drugs, the class carries precautions around pancreatitis, gallbladder issues, and thyroid tumors, which are why these medications require provider oversight rather than casual use.

Frequently Asked Questions

Is CagriSema harder to tolerate than Ozempic or Wegovy?

It tends to cause more gastrointestinal side effects, since it combines two appetite-regulating drugs rather than one. However, the trials found that most side effects were mild to moderate and that discontinuation rates stayed relatively low, suggesting the added tolerability burden is manageable for most people.

Do the side effects go away?

For most people, yes. Gastrointestinal symptoms are worst during the dose-escalation phase and typically improve significantly once a stable maintenance dose is reached. Constipation can linger longer in some people but is usually manageable.

Is CagriSema available now?

No. CagriSema is investigational and not FDA approved. Novo Nordisk filed for FDA approval in late 2025, with a review expected in 2026. It’s only available through clinical trials, and TrimRx does not offer it.

If you’d rather focus on treatments available today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. CagriSema is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.